# A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)

> **NCT05067244** · PHASE2 · COMPLETED · sponsor: **Remedy** · enrollment: 10 (actual)

## Conditions studied

- Post Traumatic Stress Disorder

## Interventions

- **DRUG:** MDMA

## Key facts

- **NCT ID:** NCT05067244
- **Lead sponsor:** Remedy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-04
- **Primary completion:** 2024-11-01
- **Final completion:** 2024-11-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2024-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05067244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05067244, "A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05067244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*